The Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study

Launched by RUIJIN HOSPITAL · Dec 18, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to use advanced imaging technology called PET/CT, combined with artificial intelligence, to help doctors better understand and treat a type of cancer known as T-NK cell lymphoma. The goal is to create a model that can accurately predict how patients will respond to treatment and what their future health might look like based on their imaging results. This could potentially give doctors more precise tools to make treatment decisions.

To participate in this trial, patients need to have a confirmed diagnosis of T-NK cell lymphoma and must undergo a specific type of imaging test (the 18F-FDG PET/CT) before starting their treatment. It's important that they have complete medical information available for the researchers. However, those who have already received cancer treatment, have other types of tumors, or do not have all the required medical information will not be eligible. This trial is not yet recruiting participants, but it aims to gather important data that could improve how this type of lymphoma is diagnosed and treated in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Pathological histology confirmed as T-NK Cell Lymphoma; 2.18F-FDG PET/CT examination before treatment; 3. Using modern best practice treatment options; 4. Complete clinicopathological and follow-up data were obtained.
• Exclusion Criteria:
• • 1. The patient had previously received antitumor therapy;
• • 2. The patient had a history of other tumors;
• • 3. Incomplete clinical information or imaging data;
• • 4. Concomitant other malignant tumors.